Total Payments
$112,100
2023 Payments
$31,375
Companies
1
Transactions
21
Medicare Patients
7,016
Medicare Billing
$280,193
Payment Breakdown by Category
Research$112,100 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $112,100 | 21 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Endo Pharmaceuticals Inc. | $112,100 | 21 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $31,375 | 6 | Endo Pharmaceuticals Inc. ($31,375) |
| 2022 | $27,625 | 5 | Endo Pharmaceuticals Inc. ($27,625) |
| 2021 | $51,450 | 9 | Endo Pharmaceuticals Inc. ($51,450) |
| 2020 | $1,650 | 1 | Endo Pharmaceuticals Inc. ($1,650) |
All Payment Transactions
21 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 01/11/2023 | Endo Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $16,000.00 | Research |
| Study: Observational, Investigator blinded, Long-Term Post-injection Study to Evaluate the Safety and Durability (Efficacy) of Response to EN3835 compared to placebo in the Treatment of Adhesive Capsulitis of the shoulder (Frozen Shoulder) | ||||||
| 01/11/2023 | Endo Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $3,750.00 | Research |
| Study: Observational, Investigator blinded, Long-Term Post-injection Study to Evaluate the Safety and Durability (Efficacy) of Response to EN3835 compared to placebo in the Treatment of Adhesive Capsulitis of the shoulder (Frozen Shoulder) | ||||||
| 01/11/2023 | Endo Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $3,289.50 | Research |
| Study: Observational, Investigator blinded, Long-Term Post-injection Study to Evaluate the Safety and Durability (Efficacy) of Response to EN3835 compared to placebo in the Treatment of Adhesive Capsulitis of the shoulder (Frozen Shoulder) | ||||||
| 01/11/2023 | Endo Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $3,085.50 | Research |
| Study: Observational, Investigator blinded, Long-Term Post-injection Study to Evaluate the Safety and Durability (Efficacy) of Response to EN3835 compared to placebo in the Treatment of Adhesive Capsulitis of the shoulder (Frozen Shoulder) | ||||||
| 01/11/2023 | Endo Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $3,000.00 | Research |
| Study: Observational, Investigator blinded, Long-Term Post-injection Study to Evaluate the Safety and Durability (Efficacy) of Response to EN3835 compared to placebo in the Treatment of Adhesive Capsulitis of the shoulder (Frozen Shoulder) | ||||||
| 01/11/2023 | Endo Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $2,250.00 | Research |
| Study: Observational, Investigator blinded, Long-Term Post-injection Study to Evaluate the Safety and Durability (Efficacy) of Response to EN3835 compared to placebo in the Treatment of Adhesive Capsulitis of the shoulder (Frozen Shoulder) | ||||||
| 06/14/2022 | Endo Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $2,500.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF EN3835 FOR THE TREATMENT OF ADHESIVE CAPSULITIS OF THE SHOULDER | ||||||
| 06/14/2022 | Endo Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $2,000.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF EN3835 FOR THE TREATMENT OF ADHESIVE CAPSULITIS OF THE SHOULDER | ||||||
| 03/08/2022 | Endo Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $10,375.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF EN3835 FOR THE TREATMENT OF ADHESIVE CAPSULITIS OF THE SHOULDER | ||||||
| 02/15/2022 | Endo Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $5,625.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF EN3835 FOR THE TREATMENT OF ADHESIVE CAPSULITIS OF THE SHOULDER | ||||||
| 02/01/2022 | Endo Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $7,125.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF EN3835 FOR THE TREATMENT OF ADHESIVE CAPSULITIS OF THE SHOULDER | ||||||
| 11/30/2021 | Endo Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $8,975.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF EN3835 FOR THE TREATMENT OF ADHESIVE CAPSULITIS OF THE SHOULDER | ||||||
| 11/16/2021 | Endo Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $6,000.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF EN3835 FOR THE TREATMENT OF ADHESIVE CAPSULITIS OF THE SHOULDER | ||||||
| 10/19/2021 | Endo Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $8,975.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF EN3835 FOR THE TREATMENT OF ADHESIVE CAPSULITIS OF THE SHOULDER | ||||||
| 09/28/2021 | Endo Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $3,950.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF EN3835 FOR THE TREATMENT OF ADHESIVE CAPSULITIS OF THE SHOULDER | ||||||
| 08/10/2021 | Endo Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $9,750.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF EN3835 FOR THE TREATMENT OF ADHESIVE CAPSULITIS OF THE SHOULDER | ||||||
| 06/22/2021 | Endo Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $5,200.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF EN3835 FOR THE TREATMENT OF ADHESIVE CAPSULITIS OF THE SHOULDER | ||||||
| 05/11/2021 | Endo Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $2,875.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF EN3835 FOR THE TREATMENT OF ADHESIVE CAPSULITIS OF THE SHOULDER | ||||||
| 04/13/2021 | Endo Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $2,225.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF EN3835 FOR THE TREATMENT OF ADHESIVE CAPSULITIS OF THE SHOULDER | ||||||
| 03/30/2021 | Endo Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $3,500.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF EN3835 FOR THE TREATMENT OF ADHESIVE CAPSULITIS OF THE SHOULDER | ||||||
| 11/24/2020 | Endo Pharmaceuticals Inc. | XIAFLEX (Biological) | — | Cash or cash equivalent | $1,650.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF EN3835 FOR THE TREATMENT OF ADHESIVE CAPSULITIS OF THE SHOULDER • Category: ORTHOPEDIC | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF EN3835 FOR THE TREATMENT OF ADHESIVE CAPSULITIS OF THE SHOULDER | Endo Pharmaceuticals Inc. | $80,725 | 15 |
| Observational, Investigator blinded, Long-Term Post-injection Study to Evaluate the Safety and Durability (Efficacy) of Response to EN3835 compared to placebo in the Treatment of Adhesive Capsulitis of the shoulder (Frozen Shoulder) | Endo Pharmaceuticals Inc. | $31,375 | 6 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 53 | 2,450 | 2,667 | $252,650 | $75,723 |
| 2022 | 41 | 1,968 | 2,206 | $262,750 | $81,950 |
| 2021 | 26 | 1,420 | 1,579 | $209,645 | $67,020 |
| 2020 | 23 | 1,178 | 1,268 | $173,370 | $55,499 |
Total Patients
7,016
Total Services
7,720
Medicare Billing
$280,193
Procedure Codes
144
All Medicare Procedures & Services
144 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 70450 | Ct scan head or brain without contrast | Facility | 2023 | 371 | 429 | $45,045 | $13,628 | 30.3% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Facility | 2023 | 116 | 121 | $26,620 | $8,478 | 31.8% |
| 72125 | Ct scan of upper spine without contrast | Facility | 2023 | 117 | 121 | $15,730 | $4,616 | 29.3% |
| 70496 | Ct scan of blood vessels of head with contrast | Facility | 2023 | 66 | 67 | $14,405 | $4,466 | 31.0% |
| 70498 | Ct scan of blood vessels of neck with contrast | Facility | 2023 | 58 | 59 | $12,390 | $3,829 | 30.9% |
| 74176 | Ct scan of abdomen and pelvis without contrast | Facility | 2023 | 55 | 56 | $11,760 | $3,778 | 32.1% |
| 70553 | Mri scan of brain before and after contrast | Facility | 2023 | 44 | 44 | $12,100 | $3,748 | 31.0% |
| 71045 | X-ray of chest, 1 view | Facility | 2023 | 284 | 346 | $6,920 | $2,500 | 36.1% |
| 70551 | Mri scan of brain without contrast | Facility | 2023 | 42 | 42 | $8,610 | $2,315 | 26.9% |
| 71275 | Ct scan of blood vessels of chest with contrast | Facility | 2023 | 29 | 29 | $6,380 | $2,029 | 31.8% |
| 71046 | X-ray of chest, 2 views | Facility | 2023 | 222 | 232 | $5,800 | $1,901 | 32.8% |
| 74230 | Imaging for evaluation of swallowing function | Facility | 2023 | 83 | 85 | $5,525 | $1,770 | 32.0% |
| 72148 | Mri scan of lower spinal canal without contrast | Facility | 2023 | 30 | 30 | $6,150 | $1,650 | 26.8% |
| 71260 | Ct scan of chest with contrast | Facility | 2023 | 34 | 35 | $5,250 | $1,582 | 30.1% |
| 72158 | Mri scan of lower spinal canal before and after contrast | Facility | 2023 | 15 | 15 | $4,200 | $1,348 | 32.1% |
| 76377 | 3d radiographic procedure with computerized image postprocessing | Facility | 2023 | 19 | 31 | $3,100 | $986.42 | 31.8% |
| 71250 | Ct scan of chest without contrast | Facility | 2023 | 21 | 21 | $2,625 | $899.70 | 34.3% |
| 70491 | Ct scan of soft tissue of neck with contrast | Facility | 2023 | 17 | 17 | $2,890 | $888.27 | 30.7% |
| 20610 | Aspiration and/or injection of fluid from large joint | Facility | 2023 | 16 | 21 | $4,800 | $861.99 | 18.0% |
| 72141 | Mri scan of upper spinal canal without contrast | Facility | 2023 | 14 | 14 | $2,870 | $829.26 | 28.9% |
| 93970 | Ultrasound study of arm or leg veins with compression and maneuvers | Facility | 2023 | 30 | 30 | $2,400 | $806.20 | 33.6% |
| 72131 | Ct scan of lower spine without contrast | Facility | 2023 | 20 | 20 | $2,500 | $761.54 | 30.5% |
| 74240 | Single contrast x-ray of upper digestive tract | Facility | 2023 | 22 | 24 | $3,240 | $745.20 | 23.0% |
| 70486 | Ct scan of face without contrast | Facility | 2023 | 24 | 24 | $2,760 | $730.78 | 26.5% |
| 76705 | Limited ultrasound scan of abdomen | Facility | 2023 | 32 | 33 | $2,475 | $730.22 | 29.5% |
About Dr. Michael Baldwin, MD
Dr. Michael Baldwin, MD is a Pediatric Radiology healthcare provider based in Farmington, Connecticut. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/30/2006. The National Provider Identifier (NPI) number assigned to this provider is 1467529701.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Baldwin, MD has received a total of $112,100 in payments from pharmaceutical and medical device companies, with $31,375 received in 2023. These payments were reported across 21 transactions from 1 company. The most common payment nature is "" ($112,100).
As a Medicare-enrolled provider, Baldwin has provided services to 7,016 Medicare beneficiaries, totaling 7,720 services with total Medicare billing of $280,193. Data is available for 4 years (2020–2023), covering 144 distinct procedure/service records.
Ad
Practice Information
- Specialty Pediatric Radiology
- Other Specialties Diagnostic Radiology, Diagnostic Radiology
- Location Farmington, CT
- Active Since 11/30/2006
- Last Updated 09/26/2022
- Taxonomy Code 2085P0229X
- Entity Type Individual
- NPI Number 1467529701
Products in Payments
- XIAFLEX (Biological) $1,650
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.